Clinical Trials Browser

Has results × Lung Neoplasms × brigatinib × Clear all

NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT03420742 2023-01-27

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Phase 1 Completed

24 enrolled 17 charts

Carcinoma, Lung Neoplasms, Neoplasms

NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

Phase 2 Terminated

1 enrolled 6 charts

Brain Neoplasms, Lung Neoplasms

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell